Menopause represents an endocrine challenge to urogenital health, as oestrogens deprivation and androgens decline significantly contributes to age-related involution of vulvovaginal tissues and lower urinary tract. Genitourinary syndrome of menopause (GSM) is a clinical entity including the chronic and progressive condition of vulvovaginal atrophy (VVA) and encompassing both anatomical and functional consequences of menopause. The term GSM describes genital, sexual and urinary symptoms with a detrimental impact on quality of life (QOL). Several treatment options are available, but many barriers are still present to adequately diagnose and treat GSM. This review aims to present current evidences about epidemiology, aetiology, diagnosis and treatment of GSM, with a focus on prescription medications [low-dose local oestrogen therapy (LET), prasterone (DHEA) and the SERM ospemifene] for urogenital symptoms in healthy postmenopausal women and in special populations, including women with premature ovarian insufficiency (POI) and breast cancer survivors (BCS).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.beem.2021.101595 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.
Cancer Immunol Immunother
January 2025
Oncology Unit, Macerata Hospital, Macerata, Italy.
Introduction: Renal cell carcinoma (RCC) is one of the most common types of urogenital cancer. The introduction of immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase inhibitors (TKIs), has radically changed the treatment landscape for metastatic RCC, showing varying efficacy across different prognostic groups based on the International Metastatic RCC Database Consortium (IMDC) criteria.
Materials And Methods: This retrospective multicenter study, part of the ARON-1 project, aimed to evaluate the outcomes of favorable-risk metastatic RCC patients treated with immune-based combinations or sunitinib.
Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.
J Neurol
January 2025
Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Background And Objective: Non-motor symptoms frequently develop throughout the disease course of Parkinson's disease (PD), and pose affected individuals at risk of complications, more rapid disease progression and poorer quality of life. Addressing such symptom burden, the 2023 revised "Parkinson's disease" guideline of the German Society of Neurology aimed at providing evidence-based recommendations for managing PD non-motor symptoms, including autonomic failure, pain and sleep disturbances.
Methods: Key PICO (Patient, Intervention, Comparison, Outcome) questions were formulated by the steering committee and refined by the assigned authors.
Enhancing lithotripsy efficiency in retrograde intrarenal surgery via a flexible kidney-fixed position: findings from a prospective cohort study.
Urolithiasis
January 2025
Department of Urology, The First Affiliated Hospital of Anhui Medical University, 100 Huaihai Road, Hefei, Anhui, 230000, China.
Retrograde intrarenal surgery (RIRS) is recognized as an effective intervention for renal stones measuring less than 20 mm. This study aims to assess the efficacy and safety of a novel flexible kidney-fixed position compared to the conventional lithotomy position, focusing on lithotripsy efficiency and stone-free rates (SFR). A total of 100 patients undergoing unilateral RIRS between January 2023 and September 2024 were randomly allocated to either the conventional lithotomy position group or the kidney-fixed position group.
View Article and Find Full Text PDFReal-world analysis of medications inducing meibomian gland dysfunction: based on the FDA adverse event reporting system database.
Expert Opin Drug Saf
January 2025
Eye Institute & Affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Background: Dry eye syndrome (DES) has become a significant public health issue, impacting quality of life. Meibomian Gland Dysfunction (MGD) is a primary contributor to DES, and its etiology includes diverse factors. Given the potential for drug-induced MGD, comprehensive investigation into this association is crucial.
View Article and Find Full Text PDFThe effect of coadministration of vitamin D and tramadol on serum kisspeptin, testosterone, oxidative stress levels and testicular histology in Wistar rats: a preliminary report.
Rev Int Androl
December 2024
Department of Human Physiology, Faculty of Basic Medical Sciences, College of Health Sciences, Nnamdi Azikiwe University, Nnewi Campus, P.O. Box 5001, 435101 Nnewi, AN, Nigeria.
Background: Tramadol, an opioid analgesic, is known to induce testicular damage and impair reproductive parameters. Vitamin D3, recognized for its antioxidant and protective properties, might offer a potential protective effect against tramadol-induced testicular damage. This study observed the effects of co-administration of vitamin D3 and tramadol on serum kisspeptin levels, testicular histology, semen parameters, testosterone levels, and oxidative stress markers in male rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!